Ioannis Gounaris
Vice President - Clinical Development EMD Serono
Seminars
• Highlighting the key reasons DDR programs stall, including weak mechanistic rationale, limited biomarker support, and poor patient stratification
• Presenting real-world case studies from biotech and academia on programs that failed to translate, and the lessons learned
• Exploring how early decisions around target selection, dosing, and trial design impact clinical success
• Identifying practical strategies to improve target validation, including functional assays, predictive biomarkers, and more robust preclinical models
• See how Merck is demonstrating durable responses with ATR inhibition in ATRX-mutant gliomas, a poor-prognosis subtype
• Outlining the synthetic lethality rationale linking ATRX loss, alternative lengthening of telomeres (ALT), and ATR dependency
• Presenting ongoing studies confirming early signals and discussing opportunities to integrate biomarker-driven patient selection into glioma trial design
